What Forced CMS to Terminate the MA Value-Based Insurance Design Model?
Calling the costs ‘unprecedented’ in CMS Innovation Center models, the VBID model cost CMS $2.3 billion in CY 2021 and $2.2 billion in CY 2022
Read More
Policy Changes Bring Renewed Focus on High-Deductible Health Plans
Policy changes, anticipated increases in premium costs for enrollees, and new standards for health savings accounts may encourage consumers to seek out plans with lower premiums but higher deductibles. This issue brief explores the features of bronze and catastrophic plans, coverage and costs, and the complicated choices consumers face.
AVIA Acquires Panda Health
Panda Health, AVIA Marketplace will combine to connects buyers and sellers of digital health technologies
5 Key Facts on Adolescent Mental Health and Substance Use Disorders
Nineteen percent of adolescents experience moderate to severe anxiety and 2 million have a substance use disorder. This analysis covers the latest data on adolescent mental illness, suicide and drug overdose trends, and access to care.
Why Providence Wants to Sell Its Health Plan
Providence announced its intent to sell its health plan, exiting the “payvider” model as rising costs and operational complexity weigh on smaller regional insurers. The move reflects a broader trend of health systems refocusing on core care delivery and exploring partnerships instead of running insurance themselves. The post Why Providence Wants to Sell Its Health…
A Look at the Potential Impact of the High Unemployment Hardship Exception to Medicaid Work Requirements
This issue brief describes the hardship exception for individuals living in counties with high unemployment, and using the most recent available county-level unemployment data, estimates the number of counties that could meet the criteria for this exception and the number of expansion enrollees living in those counties who could be exempt from work requirements.
CBRE Report: Post-Pandemic Slowdown Now Evident in Oversupply of Biotech Labs
Laboratory construction has waned in the past two years due to the end of the pandemic and an economic slowdown, according to a new report from CBRE. The firm predicts in-progress lab construction will decline to pre-pandemic levels by 2026. The post CBRE Report: Post-Pandemic Slowdown Now Evident in Oversupply of Biotech Labs appeared first…
Calling BS
By KIM BELLARD We are living, you’d have to say, in the age of bullshit. Our politicians can’t answer the simplest of questions without spouting word salad answers aimed at running out the clock until the next question. Our corporations spew endless platitudes about their lofty goals in an attempt to distract us from their…
5 Notable Health Tech Funding Announcements in December
Health tech companies made several major funding announcements in December. Here is a list of some of the biggest funding rounds. The post 5 Notable Health Tech Funding Announcements in December appeared first on MedCity News.
Skye Bio Obesity Drug Fails in Phase 2; Hopes Now Ride on Higher Doses and Combo Treatment
While Skye Bioscience said its drug nimacimab may yet achieve better weight loss results with higher doses, the company and analysts are interested in the drug’s potential to be combined with Novo Nordisk’s Wegovy. Skye’s drug is an antibody designed to preferentially target CB1 receptors in the gut, offering an alternative approach to activating GLP-1…